Management of neovascular age-related macular degeneration: Taiwan expert consensus

Neovascular age-related macular degeneration (nAMD) is a leading cause of irreversible vision loss. The present consensus provides suggestions on diagnosis, evaluation, treatment, and follow-up strategies for nAMD from a panel of 11 practicing ophthalmologists. The experts suggest that the baseline...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ling Yeung, Yi-Ting Hsieh, Chang-Hao Yang, Lee-Jen Chen, Shih-Jen Chen, Cheng-Kuo Cheng, Shwu-Jiuan Sheu, Ching-Yao Tsai, Tsung-Tien Wu, Wei-Chi Wu, San-Ni Chen
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Neovascular age-related macular degeneration Wet age-related macular degeneration Vascular endothelial growth factors Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/16b4c37f5d8143fcaa6c8ba3dab77e1d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:16b4c37f5d8143fcaa6c8ba3dab77e1d
record_format	dspace
spelling	oai:doaj.org-article:16b4c37f5d8143fcaa6c8ba3dab77e1d2021-12-02T04:59:12ZManagement of neovascular age-related macular degeneration: Taiwan expert consensus0929-664610.1016/j.jfma.2021.06.012https://doaj.org/article/16b4c37f5d8143fcaa6c8ba3dab77e1d2021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S0929664621002928https://doaj.org/toc/0929-6646Neovascular age-related macular degeneration (nAMD) is a leading cause of irreversible vision loss. The present consensus provides suggestions on diagnosis, evaluation, treatment, and follow-up strategies for nAMD from a panel of 11 practicing ophthalmologists. The experts suggest that the baseline visit for nAMD management should include a comprehensive ophthalmologic examination via a multimodal approach consisting of visual and anatomical evaluation. Patients diagnosed with nAMD should be subjected to treatment with the goal of maintaining visual function while diminishing anatomical disease activity and minimizing treatment burden. Currently, anti-VEGF therapy is the main treatment strategy for nAMD, and evaluation involving comprehensive ophthalmologic examination within 1 month of completion of the loading phase comprising three monthly injections is recommended to guide subsequent management. Either a treat-and-extend or pro re nata regimen can be considered for the maintenance phase of anti-VEGF therapy, and the regimen should be chosen and adjusted according to disease activity, reimbursement criteria, financial burden, and patient preferences. In the event of inactive nAMD or poor treatment outcomes, after thorough evaluation and patient education, anti-VEGF therapy may be stopped. The consensus provides practical nAMD management guidelines for ophthalmologists and fellow healthcare professionals.Ling YeungYi-Ting HsiehChang-Hao YangLee-Jen ChenShih-Jen ChenCheng-Kuo ChengShwu-Jiuan SheuChing-Yao TsaiTsung-Tien WuWei-Chi WuSan-Ni ChenElsevierarticleNeovascular age-related macular degenerationWet age-related macular degenerationVascular endothelial growth factorsMedicine (General)R5-920ENJournal of the Formosan Medical Association, Vol 120, Iss 12, Pp 2061-2071 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neovascular age-related macular degeneration Wet age-related macular degeneration Vascular endothelial growth factors Medicine (General) R5-920
spellingShingle	Neovascular age-related macular degeneration Wet age-related macular degeneration Vascular endothelial growth factors Medicine (General) R5-920 Ling Yeung Yi-Ting Hsieh Chang-Hao Yang Lee-Jen Chen Shih-Jen Chen Cheng-Kuo Cheng Shwu-Jiuan Sheu Ching-Yao Tsai Tsung-Tien Wu Wei-Chi Wu San-Ni Chen Management of neovascular age-related macular degeneration: Taiwan expert consensus
description	Neovascular age-related macular degeneration (nAMD) is a leading cause of irreversible vision loss. The present consensus provides suggestions on diagnosis, evaluation, treatment, and follow-up strategies for nAMD from a panel of 11 practicing ophthalmologists. The experts suggest that the baseline visit for nAMD management should include a comprehensive ophthalmologic examination via a multimodal approach consisting of visual and anatomical evaluation. Patients diagnosed with nAMD should be subjected to treatment with the goal of maintaining visual function while diminishing anatomical disease activity and minimizing treatment burden. Currently, anti-VEGF therapy is the main treatment strategy for nAMD, and evaluation involving comprehensive ophthalmologic examination within 1 month of completion of the loading phase comprising three monthly injections is recommended to guide subsequent management. Either a treat-and-extend or pro re nata regimen can be considered for the maintenance phase of anti-VEGF therapy, and the regimen should be chosen and adjusted according to disease activity, reimbursement criteria, financial burden, and patient preferences. In the event of inactive nAMD or poor treatment outcomes, after thorough evaluation and patient education, anti-VEGF therapy may be stopped. The consensus provides practical nAMD management guidelines for ophthalmologists and fellow healthcare professionals.
format	article
author	Ling Yeung Yi-Ting Hsieh Chang-Hao Yang Lee-Jen Chen Shih-Jen Chen Cheng-Kuo Cheng Shwu-Jiuan Sheu Ching-Yao Tsai Tsung-Tien Wu Wei-Chi Wu San-Ni Chen
author_facet	Ling Yeung Yi-Ting Hsieh Chang-Hao Yang Lee-Jen Chen Shih-Jen Chen Cheng-Kuo Cheng Shwu-Jiuan Sheu Ching-Yao Tsai Tsung-Tien Wu Wei-Chi Wu San-Ni Chen
author_sort	Ling Yeung
title	Management of neovascular age-related macular degeneration: Taiwan expert consensus
title_short	Management of neovascular age-related macular degeneration: Taiwan expert consensus
title_full	Management of neovascular age-related macular degeneration: Taiwan expert consensus
title_fullStr	Management of neovascular age-related macular degeneration: Taiwan expert consensus
title_full_unstemmed	Management of neovascular age-related macular degeneration: Taiwan expert consensus
title_sort	management of neovascular age-related macular degeneration: taiwan expert consensus
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/16b4c37f5d8143fcaa6c8ba3dab77e1d
work_keys_str_mv	AT lingyeung managementofneovascularagerelatedmaculardegenerationtaiwanexpertconsensus AT yitinghsieh managementofneovascularagerelatedmaculardegenerationtaiwanexpertconsensus AT changhaoyang managementofneovascularagerelatedmaculardegenerationtaiwanexpertconsensus AT leejenchen managementofneovascularagerelatedmaculardegenerationtaiwanexpertconsensus AT shihjenchen managementofneovascularagerelatedmaculardegenerationtaiwanexpertconsensus AT chengkuocheng managementofneovascularagerelatedmaculardegenerationtaiwanexpertconsensus AT shwujiuansheu managementofneovascularagerelatedmaculardegenerationtaiwanexpertconsensus AT chingyaotsai managementofneovascularagerelatedmaculardegenerationtaiwanexpertconsensus AT tsungtienwu managementofneovascularagerelatedmaculardegenerationtaiwanexpertconsensus AT weichiwu managementofneovascularagerelatedmaculardegenerationtaiwanexpertconsensus AT sannichen managementofneovascularagerelatedmaculardegenerationtaiwanexpertconsensus
_version_	1718400875665293312

Management of neovascular age-related macular degeneration: Taiwan expert consensus

Ejemplares similares